Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.
Back to dashboard
Company Information
About this company
Key people
Fredrik Alpsten
Independent Chairman of the Board
Cornelis Peters Bogerd
Director
Annika Carlsson Berg
Independent Director
Marie-Louise Fjallskog
Independent Director
Theis Kipling
Chief Executive Officer
Anders Moren
Chief Financial Officer
Hanna Ritzen
Senior Vice President - Global Marketing and Business Development
Henrik Winther
Senior Vice President - Business Development
Sofia Loehman
Vice President - Quality Assurance and Regulatory Affairs
Rickard Boman
Vice President - Research & Development and Production
Hector Tamburini
Head of US Laboratory Operations, Regulatory & Quality
Anders Rylander
Director
Click to see more
Key facts
- Shares in issue277.49m
- EPICBIOVIC B
- ISINSE0008613731
- LocationSweden
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market capSEK 136.80m
- Employees25
- ExchangeStockholm Stock Exchange
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.